Guardant Health

Guardant Health, based in Palo Alto, California, is a biotechnology company focused on providing advanced cancer diagnostics and sequencing services. Their core mission is to conquer cancer through data, utilizing blood tests to uncover critical information that aids in early detection and treatment optimization. Guardant Health serves a global market, offering innovative solutions like the Shield blood test, which has shown potential in closing the colorectal cancer screening gap.

Guardant Health has achieved significant milestones, including the publication of their ECLIPSE study results in The New England Journal of Medicine. This study, involving over 10,000 patients, reinforces the validity of their Shield blood test. The company's impact is substantial, contributing to the early detection and improved treatment of cancer worldwide.